[Pubmed] The Duke Myasthenia Gravis Clinic Registry: II. Analysis of Outcomes

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 2979
Enregistré le : 31 mai 2020 09:57
3
Zodiaque :
Âge : 20
Contact :
    Android Chrome

[Pubmed] The Duke Myasthenia Gravis Clinic Registry: II. Analysis of Outcomes

Message par RSS-Bot »


Muscle Nerve. 2023 Feb 3. doi: 10.1002/mus.27794. Online ahead of print.

ABSTRACT

INTRODUCTION/AIMS: The Duke Myasthenia Gravis (MG) Clinic Registry contains comprehensive physician-derived data on patients with MG seen in the Duke MG Clinic since 1980. The aim of this study was to report outcomes in patients seen in the Clinic and treated according to the International Consensus Guidance statements.

METHODS: This is a retrospective cohort study of patients initially seen after 2000 and followed for at least 2 years in the Clinic. Treatment Goal (TG) was defined as achieving MGFA Post-Intervention Status (PIS) Minimal Manifestations or better; PIS was determined by the treating neurologist. Time-to-event analysis, including Cox proportional hazards modeling, was performed to assess the effect of sex, acetylcholine receptor antibody (AChR-Ab) status, age at disease onset, distribution (ocular vs generalized), thymectomy and thymoma on the time to achieve TG.

RESULTS: Among the 367 cohort patients, 72% achieved TG (median time less than 2 years). A greater proportion of patients with AChR-Abs and thymectomy achieved TG and they did so sooner than patients without these antibodies or thymectomy. Otherwise there were no significant differences in these findings within the tested subgroups. The disease duration at the first Duke Clinic visit was less in patients who achieved TG than in those who did not.

DISCUSSION: These results demonstrate outcomes that can be achieved in patients with MG treated according to the current Consensus Guidance statements. Among other things, they can be used to determine the added value and potential role of new treatment modalities developed since 2018. This article is protected by copyright. All rights reserved.

PMID:36734303 | DOI:10.1002/mus.27794


Source: https://pubmed.ncbi.nlm.nih.gov/3673430 ... t6+86293ac
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur association.amis-modo@myasthenie.com


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »